These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2908604)

  • 61. Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
    Bouffioux C
    Eur Urol; 1988; 15(3-4):187-92. PubMed ID: 2975222
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer?
    Boccon-Gibod L
    Eur Urol; 1998; 33(2):159-64. PubMed ID: 9519357
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
    Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
    J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The development of Casodex (bicalutamide): preclinical studies.
    Furr BJ
    Eur Urol; 1996; 29 Suppl 2():83-95. PubMed ID: 8717469
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effectiveness of antiandrogens in the rat.
    Burton S; Trachtenberg J
    J Urol; 1986 Oct; 136(4):932-5. PubMed ID: 3761464
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The role of antiandrogen monotherapy in the treatment of prostate cancer.
    Anderson J
    BJU Int; 2003 Mar; 91(5):455-61. PubMed ID: 12603397
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Antiandrogens in dermatological therapy. I. Mechanism of action of antiandrogens with special reference to the skin].
    Zabel J
    Przegl Dermatol; 1984; 71(3):291-5. PubMed ID: 6240670
    [No Abstract]   [Full Text] [Related]  

  • 68. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Antiandrogens. Mechanisms and paradoxical effects].
    Mowszowicz I
    Ann Endocrinol (Paris); 1989; 50(3):189-99. PubMed ID: 2530930
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advanced prostatic carcinoma: flutamide therapy after conventional endocrine treatment.
    Sogani PC; Ray B; Whitmore WF
    Urology; 1975 Aug; 6(2):164-6. PubMed ID: 1145932
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
    Senn E; Müller J; Alioth H
    Schweiz Rundsch Med Prax; 1985 Nov; 74(48):1340-4. PubMed ID: 3003863
    [No Abstract]   [Full Text] [Related]  

  • 74. [Antiandrogen in prostate cancer].
    Maeda O; Usami M
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():188-92. PubMed ID: 12599569
    [No Abstract]   [Full Text] [Related]  

  • 75. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.
    Brogden RN; Clissold SP
    Drugs; 1989 Aug; 38(2):185-203. PubMed ID: 2670515
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
    Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
    Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
    Oosterlinck W; Mast P
    Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of two different medical treatments on dihydrotestosterone content and androgen receptors in human benign prostatic hyperplasia.
    Petrangeli E; Sciarra F; Di Silverio F; Toscano V; Lubrano C; Conti C; Concolino G
    J Steroid Biochem; 1988; 30(1-6):395-9. PubMed ID: 2455099
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A; von Angerer E
    J Cancer Res Clin Oncol; 1993; 119(11):669-74. PubMed ID: 8349724
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hormone therapy of advanced prostate cancer: where we stand today.
    Crawford ED; Nabors W
    Oncology (Williston Park); 1991 Jan; 5(1):21-30; discussion 30, 32, 37. PubMed ID: 1828686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.